Cancer Conference Update 2 | 2007 - Audio Files

You are here: Home: Audio Programs: CACU 2 | 2007: CACU 2 | 2007 Audio Files


Go to interview with Richard M Goldberg, MD Go to interview with Axel Grothey, MD Go to interview with Charles D Blanke, MD
To listen to individual tracks click the icon. To download tracks, right-click on the one you wish to download.


	Richard M Goldberg, MD Professor and Chief Division of Hematology/Oncology Associate Director University of North Carolina Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina Click here to download the entire interview		MP3

Track 1

Track 2

EVEREST: Cetuximab dose-escalation study for patients with metastatic colorectal cancer (mCRC) and no or slight skin reactions to standard-dose cetuximab

Track 3

XELOX-1/NO16966: CAPOX or FOLFOX4 with or without bevacizumab as first-line therapy

Track 4

Continuation of a fluoropyrimidine and bevacizumab after discontinuation of oxaliplatin

Track 5

Survey of patients’ and oncologists’ perspectives on adjuvant chemotherapy

Track 6

Pathologic analysis of hepatic injury after oxaliplatin-based neoadjuvant chemotherapy

Track 7

Value of PET scanning for potentially operable mCRC

Track 8

BEATrial: Bleeding events during metastectomy after bevacizumab and chemotherapy

Track 9

BEATrial: Safety and efficacy of bevacizumab with first-line chemotherapy

Track 10

Cetuximab with FOLFOX4 as first-line therapy for EGFR-expressing mCRC

Track 11

Efficacy and safety of panitumumab in mCRC

Track 12

BRiTE: Safety of bevacizumab with chemotherapy for elderly patients with mCRC

Track 13

Panitumumab activity in patients with low or negative tumor EGFR levels in mCRC

Track 14

EGFR gene status, K-ras mutations and PTEN expression predict cetuximab response

Track 15

Safety of infusing bevacizumab at 5 mg/kg over 10 minutes

Track 16

Routine antihistamine premedication after the first two doses of cetuximab

Track 17

Survival of rectal cancer with preoperative chemoradiation therapy correlates with response to treatment and not with pretreatment staging

Track 18

BRiTE: Survival of patients with mCRC treated with bevacizumab and chemotherapy

Track 19

Clinical resources utilized from infusion reactions with cetuximab and rituximab


	Axel Grothey, MD Senior Associate Consultant Department of Medical Oncology Mayo Clinic Rochester, Minnesota Click here to download the entire interview		MP3

Track 1

Track 2

Neoadjuvant oxaliplatin-containing chemotherapy in downstaging hepatic metastases for a potentially curative resection

Track 3

Complications following hepatic surgery after neoadjuvant bevacizumab

Track 4

Use of maintenance therapy versus chemotherapy-free intervals with oxaliplatin regimens

Track 5

Oxaliplatin with neoadjuvant fluoropyrimidine/radiation therapy for locally advanced or metastatic rectal cancer

Track 6

Capecitabine/oxaliplatin (CAPOX) and bevacizumab as radiosensitizers in rectal cancer

Track 7

Response prediction for cetuximab-based therapy: EGFR copy number by FISH and gene mutations

Track 8

Pharmacogenomic analysis of BOND-2: Cetuximab/bevacizumab/irinotecan versus cetuximab/bevacizumab in irinotecan-refractory colorectal cancer

Track 9

Use of chemotherapy for metastatic colorectal cancer in the elderly

Track 10

Magnitude of response to conventional chemotherapy: Lessons learned from N9741

Track 11

XELOX-1/NO16966: Efficacy of CAPOX versus FOLFOX4 as first-line therapy for mCRC

Track 12

ACCENT: Time-dependent patterns of failure and benefit with adjuvant therapy for colon cancer


	Charles D Blanke, MD Professor of Medicine OHSU Cancer Institute Portland, Oregon Click here to download the entire interview		MP3

Track 1

Track 2

Efficacy of imatinib in advanced gastrointestinal stromal tumor (GIST) according to tumor bulk

Track 3

A nomogram to predict recurrence after resection of primary GIST

Track 4

Incidence and adjuvant therapy of GIST

Track 5

Research directions in GIST

Track 6

BJSA-01: FOLFOX7 as neoadjuvant and adjuvant treatment versus adjuvant treatment alone in locally advanced resectable gastric cancer

Track 7

Therapeutic approaches to the management of gastric cancer

Track 8

Biweekly capecitabine with irinotecan for advanced or metastatic gastric cancer

Track 9

Weekly 24-hour infusion of FUDR and leucovorin with oxaliplatin and docetaxel (FLOD) as first-line therapy for metastatic gastric adenocarcinoma

Track 10

CALGB-80303: Gemcitabine with or without bevacizumab in advanced pancreatic cancer

Track 11

Cetuximab with gemcitabine/oxaliplatin for first-line metastatic pancreatic cancer

Track 12

Bevacizumab/erlotinib for gemcitabine-refractory metastatic pancreatic cancer

Track 13

Meta-analysis: Gemcitabine-based combinations in advanced pancreatic cancer

Track 14

Induction oxaliplatin and 5-FU chemoradiation therapy for locally advanced, unresectable pancreatic cancer

Track 15

Capecitabine/docetaxel for locally advanced and metastatic pancreatic cancer previously treated with gemcitabine-based therapy

Track 16

Erlotinib as single-agent therapy for advanced pancreatic cancer

Track 17

Thromboembolic events in the REAL-2 study of four chemotherapy regimens for the treatment of esophagogastric cancer

Track 18

Advances with FOLFOX and targeted therapies in the treatment of gastrointestinal malignancies

Terms and Conditions of Use | Privacy Policy
Copyright 2007 © Research To Practice. All Rights Reserved.